Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Angiogenesis is the physiological process through which new blood vessels form from pre-existing vessels. The secretion of angiogenic factors initiates a cascade involving the release of chemical signals from hypoxic or injured tissues, binding to receptors on endothelial cells, leading to endothelial cell activation, proliferation, migration, and differentiation. This process is essential for normal growth, development, wound healing, and tissue repair, but also plays a critical role in pathological conditions such as cancer. Therapeutic strategies targeting this pathway include angiogenesis inhibitors that block key molecules like VEGF or its receptor signaling pathways.
Inhibition of angiogenic factor secretion, receptor binding, or downstream signaling pathways to prevent new blood vessel formation.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Angiogenesis (secretion of angiogenic factors).